Condition
Biliary Tract Neoplasms Immunotherapy clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Biliary Tract Neoplasms Immunotherapy clinical trials that are recruiting, in China. By phase: Phase 2 (4). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest Biliary Tract Neoplasms Immunotherapy clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Trastuzumab Rezetecan with Adebrelimab and Lenvatinib for advanced HER2-positive/low-expression biliary tract cancer | Phase 2 | Beijing, Beijing Municipality | Recruiting | Jul 15, 2026 |
| Adjuvant durvalumab with GEMOX/GC chemotherapy followed by lenvatinib vs capecitabine in biliary tract cancer after surgery | Phase 2 | Beijing | Recruiting | Jul 1, 2026 |
| First-line treatment with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib for advanced HER2-positive or HER2-low biliary tract cancer | Phase 2 | Beijing | Recruiting | Jun 26, 2026 |
| Treatment options for advanced biliary tract cancer using Pembrolizumab | Phase 2 | Beijing, Beijing Municipality | Recruiting | Jan 30, 2024 |
All recruiting trials (4)
-
Trastuzumab Rezetecan with Adebrelimab and Lenvatinib for advanced HER2-positive/low-expression biliary tract cancer
This study tests a triple therapy to see if it helps people with advanced biliary tract cancer that is HER2-positive or has low HER2 expression after at least one prior treatment.
-
Adjuvant durvalumab with GEMOX/GC chemotherapy followed by lenvatinib vs capecitabine in biliary tract cancer after surgery
This trial tests whether adding durvalumab with GEMOX/GC chemotherapy followed by lenvatinib after surgery helps biliary tract cancer patients stay cancer-free longer than capecitabine alone.
-
First-line treatment with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib for advanced HER2-positive or HER2-low biliary tract cancer
This phase II trial tests whether a combination of Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib can help people with advanced HER2-positive or HER2-low biliary tract cancer respond to treatment as a first line therapy.
-
Treatment options for advanced biliary tract cancer using Pembrolizumab
This study is testing if the drug Pembrolizumab, alone or with other treatments, can help people with advanced biliary tract cancer live longer and feel better.
Related topics
Quick answers
How many Biliary Tract Neoplasms Immunotherapy clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.